8-K: Insmed's Brensocatib Shows Positive Lung Function Data in Bronchiectasis Study

Insmed announced additional positive results from its Phase 3 ASPEN study, showing that brensocatib significantly reduced lung function decline in patients with bronchiectasis.

Summary

• Insmed's ASPEN study, a Phase 3 trial, evaluated brensocatib in patients with non-cystic fibrosis bronchiectasis.
• The study met its primary endpoint, showing a significant reduction in pulmonary exacerbations with both 10 mg and 25 mg doses of brensocatib compared to placebo.
• The 25 mg dose of brensocatib demonstrated a statistically significant reduction in the decline of lung function, as measured by FEV1, with patients losing 38 mL less lung function compared to placebo over 52 weeks.
• The 25 mg dose also showed a statistically significant reduction in the decline of FVC, another measure of lung function, with patients losing 75 mL less lung function compared to placebo.
• Patients on the 25 mg dose also showed a nominally significant improvement of 3.8 points in the Quality of Life-Bronchiectasis (QOL-B) Respiratory Symptom Domain Score compared to placebo.
• The study also showed a nominally significant 1-point decrease in the average daily bronchiectasis exacerbation and symptom tool (BEST) score for the 25 mg dose compared to placebo.
• Brensocatib was well-tolerated, with a safety profile comparable to placebo.
• Insmed plans to file a New Drug Application with the FDA in the fourth quarter of 2024, with a potential U.S. launch in mid-2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results for a drug targeting an unmet medical need, with a clear path to regulatory approval and commercialization. The data is statistically significant and clinically meaningful, suggesting a high likelihood of success.

Positives

• Both doses of brensocatib significantly reduced the annualized rate of pulmonary exacerbations.
• Brensocatib significantly prolonged the time to first exacerbation.
• Brensocatib significantly increased the odds of remaining exacerbation-free.
• The 25 mg dose significantly reduced the rate of loss of lung function as measured by FEV1.
• The 25 mg dose showed a nominally significant improvement in quality of life as measured by the QOL-B RSS.
• The 25 mg dose showed a nominally significant change from baseline in FVC.
• The 25 mg dose showed a nominally significant change from baseline in the average daily BEST score.
• Brensocatib was generally well-tolerated with a favorable safety profile.

Negatives

• Some patients experienced treatment-emergent adverse events such as COVID-19, nasopharyngitis, cough, and headache, although these were generally comparable to the placebo group.
• There were some adverse events of special interest, such as hyperkeratosis and periodontitis/gingivitis, but these were not significantly higher than the placebo group.

Risks

• The full data set from the ASPEN study may not be consistent with the topline results.
• There is a risk of delays in obtaining regulatory approvals for brensocatib.
• There is a risk that brensocatib may not be successfully commercialized.
• There are uncertainties in the degree of market acceptance of brensocatib.
• There is a risk of unexpected safety or efficacy concerns related to brensocatib.
• There is a risk of failure to obtain regulatory approval for potential future brensocatib indications.
• There is a risk of failure to successfully conduct future clinical trials.
• There is a risk of failure of third parties to manufacture sufficient quantities of brensocatib.
• There is a risk of litigation, including product liability claims.
• There is a risk of business or economic disruptions due to catastrophes or other events.
• There is a risk of inability to repay existing indebtedness and uncertainties with respect to the company's need and ability to access future capital.

Future Outlook

Insmed plans to file a New Drug Application with the FDA in the fourth quarter of 2024, with a potential U.S. launch in mid-2025, followed by launches in Europe and Japan in the first half of 2026.

Management Comments

• The data announced today further underscore the positive impact brensocatib may have on patients if approved, said lead study investigator James Chalmers, MBChB, Ph.D.
• I am particularly encouraged by the data which showed that the 25 mg dose of brensocatib may slow the rate of decline of FEV1 and FVC, which represent clinically meaningful parameters of lung function that physicians consider important outcome measures.
• We are incredibly excited to share additional results from the ASPEN study with the bronchiectasis community at the World Bronchiectasis Conference, further building on the positive topline results we previously shared, said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed.
• Importantly, the additional data to be presented include exploratory endpoints that further support our belief that brensocatib may have a transformational impact on the management of bronchiectasis.

Industry Context

This announcement is significant as there are currently no approved therapies specifically targeting bronchiectasis in the U.S., Europe, and Japan, making brensocatib a potential first-in-class treatment if approved.

Comparison to Industry Standards

• Currently, there are no approved treatments for bronchiectasis, making direct comparisons difficult.
• The results of the ASPEN study, particularly the reduction in pulmonary exacerbations and the slowing of lung function decline, are promising compared to the current standard of care, which focuses on managing symptoms and exacerbations.
• The positive results for FEV1 and FVC are clinically meaningful and compare favorably to the natural progression of the disease, where lung function typically declines over time.
• The improvement in patient-reported outcomes, such as the QOL-B score, is also a positive indicator of the potential benefit of brensocatib.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and the potential for a new revenue stream.
• Patients with bronchiectasis stand to benefit from a new treatment option that could improve their lung function and quality of life.
• Physicians will have a new tool to manage bronchiectasis, a disease with limited treatment options.
• Employees of Insmed may experience increased job security and opportunities for growth.

Next Steps

• Insmed plans to file a New Drug Application with the FDA in the fourth quarter of 2024.
• Insmed anticipates a U.S. launch for brensocatib in mid-2025.
• Insmed anticipates launches in Europe and Japan in the first half of 2026.

Key Dates

Keywords

brensocatib, bronchiectasis, pulmonary exacerbations, lung function, FEV1, FVC, ASPEN study, DPP1 inhibitor, clinical trial, respiratory disease